Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07266545 · ClinicalTrials.gov registry record · Phase 4
RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)
A Phase 4 study of Bipolar Depression and Unipolar Depression, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT07266545: Recruiting Phase 4 study of Bipolar Depression and Unipolar Depression, sponsored by Mayo Clinic.
NCT07266545 is a Phase 4 study of Bipolar Depression and Unipolar Depression that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 120 participants, below the 212-participant average among 29 other Bipolar Depression trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07266545, a Phase 4 study of Bipolar Depression and Unipolar Depression, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to understand how changes in RNA editing relate to treatment response in unipolar and bipolar depression.
Primary Outcome
The Montgomery-Åsberg Depression Rating Scale (MADRS) is scored on a scale of 0 to 60, with each of the 10 items rated from 0 to 6 by a trained clinician during an interview. A higher score indicates a more severe level of depression, with common severity ranges being: 0-6 (normal), 7-19 (mild), 20-34 (moderate), and 35-60 (severe).
Conditions Studied
Interventions
- DRUG Vortioxetine
- DRUG Bupropion extended release
- DRUG Cariprazine (Augmentation Phase)
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2026-02-17 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 4 |
What NCT07266545 shows while recruiting
NCT07266545 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 212-participant average among 29 other Bipolar Depression trials with a reported enrollment target (43% lower).
The record links to 2 conditions, with Bipolar Depression appearing as the primary indexed condition, and to 3 interventions - of which Vortioxetine is the first listed.
NCT07266545 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT07266545 about?
NCT07266545 is a clinical study titled "RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)". The purpose of this research is to understand how changes in RNA editing relate to treatment response in unipolar and bipolar depression.
What is the current status of trial NCT07266545?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2026-02-17. Estimated completion is 2030-12-31.
What conditions does trial NCT07266545 study?
This clinical trial studies the following conditions: Bipolar Depression, Unipolar Depression.
What interventions are being tested in trial NCT07266545?
The interventions under investigation include: Vortioxetine (DRUG), Bupropion extended release (DRUG), Cariprazine (Augmentation Phase) (DRUG).
Who is sponsoring clinical trial NCT07266545?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07266545 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07266545's enrollment target sits among peer trials
120 11th of 29 higher than 18 of 29 other Bipolar Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bipolar Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Aripiprazole Treatment of Bipolar Depression
COMPLETED · Phase 4
-
Minocycline for Bipolar Depression
COMPLETED · Phase 4
-
Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder
RECRUITING · Early Phase 1
-
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
RECRUITING · Phase 3
-
University of Iowa Interventional Psychiatry Service Patient Registry
RECRUITING
-
Ketogenic Intervention for Bipolar Depression
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI